Seeing Is Believing
Currently out of the existing stock ratings of Srikripa Devarakonda, 59 are a BUY (92.19%), 5 are a HOLD (7.81%).
Analyst Srikripa Devarakonda, currently employed at TRUIST, carries an average stock price target met ratio of 48.57% that have a potential upside of 28.7% achieved within 132 days.
Srikripa Devarakonda’s has documented 125 price targets and ratings displayed on 15 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on KYMR, Kymera Therapeutics at 29-Sep-2025.
Analyst best performing recommendations are on SRRK (SCHOLAR ROCK HOLDING CORP).
The best stock recommendation documented was for KYMR (KYMERA THERAPEUTICS) at 11/3/2023. The price target of $41 was fulfilled within 112 days with a profit of $26.73 (187.32%) receiving and performance score of 16.72.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold
$89
$1.43 (1.63%)
$73
10 days ago
(08-Oct-2025)
10/13 (76.92%)
$4.25 (5.01%)
111
Buy
$82
11 days ago
(07-Oct-2025)
9/16 (56.25%)
$8.07 (10.92%)
107
Hold
$81
$-6.57 (-7.50%)
$72
25 days ago
(23-Sep-2025)
37/46 (80.43%)
$-3.16 (-3.75%)
272
Buy
$115
$27.43 (31.32%)
$107
27 days ago
(21-Sep-2025)
7/9 (77.78%)
$30.27 (35.73%)
204
Hold
$92
1 months ago
(18-Sep-2025)
7/11 (63.64%)
$32 (53.33%)
135
Which stock is Srikripa Devarakonda is most bullish on?
Which stock is Srikripa Devarakonda is most reserved on?
What Year was the first public recommendation made by Srikripa Devarakonda?